Clinical study of AdV-tk radiogene therapy for glioma

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$758,386.00
Award Year:
2004
Program:
SBIR
Phase:
Phase I
Contract:
1R44CA107745-01
Agency Tracking Number:
CA107745
Solicitation Year:
2004
Solicitation Topic Code:
N/A
Solicitation Number:
PHS2004-2
Small Business Information
ADVANTAGENE, INC.
ADVANTAGENE, INC., 160 PAULSON RD, WABAN, MA, 02468
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
N/A
Principal Investigator
 ESTUARDO Aguilarcordova
 (617) 916-5445
 EAGUILAR@ADVANTAGENE.COM
Business Contact
 AMANDA DAVIS
Phone: (617) 916-5445
Email: ADAVIS@ADVANTAGENE.COM
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease with great need of novel therapeutic approaches. Within cancer gene therapy the use of adenovir

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government